Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Omix AI is a biotechnology company specializing in the development of artificial intelligence platforms for multi-omics data analysis. The company's core technology focuses on single-cell and spatial transcriptomics, providing researchers with high-resolution insights into tissue microenvironments and cellular interactions. By leveraging advanced machine learning algorithms, Omix AI facilitates the discovery of novel biomarkers and the validation of therapeutic targets for complex diseases. Their platform is designed to streamline the interpretation of large-scale biological datasets, supporting drug discovery and development for pharmaceutical and academic clients. The company aims to advance precision medicine by bridging the gap between complex omics data and actionable clinical insights.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Omix AI.